Search
Patexia Research
Case number 1:23-cv-00133

AbbVie Inc. v. Teva Pharmaceuticals, Inc. > Documents

Date Field Doc. No.Description (Pages)
Jun 26, 2023 11 ANSWER to 9 Answer to Complaint and Counterclaims, by AbbVie Inc..(Tigan, Jeremy) Modified on 6/26/2023 (nms). (Entered: 06/26/2023) (6)
Jun 5, 2023 9 ANSWER to 1 Complaint, Affirmative Defenses and COUNTERCLAIMS against AbbVie Inc., by Teva Pharmaceuticals, Inc..(Hoeschen, Nathan) Modified on 6/5/2023 (nms). (Entered: 06/05/2023) (19)
Jun 5, 2023 10 Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate Teva Pharmaceutical Industries Ltd. for Teva Pharmaceuticals, Inc. filed by Teva Pharmaceuticals, Inc.. (Hoeschen, Nathan) (Entered: 06/05/2023) (1)
May 4, 2023 8 MOTION for Pro Hac Vice Appearance of Attorney Jennifer H. Roscetti, Danielle A. Duszczyszyn, William B. Raich, Constance P. Lee, Ryan V. McDonnell and Reinaldo Franqui Machin - filed by AbbVie Inc.. (Tigan, Jeremy) (Entered: 05/04/2023) (10)
May 4, 2023 N/A SO ORDERED, re (D.I. 6 in 23-cv-362-RGA; D.I. 8 in 23-cv-133-RGA) MOTION for Pro Hac Vice Appearance of Attorney Jennifer H. Roscetti, Danielle A. Duszczyszyn, William B. Raich, Constance P. Lee, Ryan V. McDonnell and Reinaldo Franqui Machin, filed by AbbVie Inc.. Signed by Judge Richard G. Andrews on 5/4/2023. Associated Cases: 1:23-cv-00133-RGA, 1:23-cv-00362-RGA(nms) (Entered: 05/04/2023) (0)
Apr 20, 2023 6 STIPULATION and [Proposed] Order Regarding Teva Defendants by AbbVie Inc.. (Tigan, Jeremy) (Entered: 04/20/2023) (5)
Apr 20, 2023 7 SO ORDERED Granting 6 Stipulation and Proposed Order (*Party Teva Pharmaceutical Industries Ltd. terminated) (*Reset Answer Deadlines: Teva Pharmaceuticals, Inc. answer due 6/5/2023). Signed by Judge Richard G. Andrews on 4/20/2023. (nms) (Entered: 04/20/2023) (5)
Feb 8, 2023 N/A Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) (Entered: 02/08/2023) (0)
Feb 3, 2023 1 COMPLAINT for Patent Infringement against Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals, Inc. (Filing fee $ 402, receipt number ADEDC-4059778) - filed by AbbVie Inc. (Attachments: # 1 Exhibits A-B, # 2 Civil Cover Sheet)(twk) Modified on 6/6/2023 (nms). (Entered: 02/03/2023) (Main Document) (18)
Feb 3, 2023 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (twk) (Entered: 02/03/2023) (3)
Feb 3, 2023 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: December 22, 2022. Date NDA Holder Received Notice: December 22, 2022. Date of Expiration of U.S. Patent No. 10,881,659: March 14, 2034. Date of Expiration of U.S. Patent No. 11,045,470: March 14, 2034. Hatch-Waxman Regulatory Exclusivity Deadline: January 23, 2026. (twk) (Entered: 02/03/2023) (2)
Feb 3, 2023 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,881,659 B2; 11,045,470 B2. (twk) (Entered: 02/03/2023) (1)
Feb 3, 2023 5 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by AbbVie Inc. (twk) (Entered: 02/03/2023) (1)
Feb 3, 2023 N/A No Summons Issued. (twk) (Entered: 02/03/2023) (0)
Feb 3, 2023 1 COMPLAINT for Patent Infringement against Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals, Inc. (Filing fee $ 402, receipt number ADEDC-4059778) - filed by AbbVie Inc. (Attachments: # 1 Exhibits A-B, # 2 Civil Cover Sheet)(twk) Modified on 6/6/2023 (nms). (Entered: 02/03/2023) (Exhibit A-B) (30)
Feb 3, 2023 1 COMPLAINT for Patent Infringement against Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals, Inc. (Filing fee $ 402, receipt number ADEDC-4059778) - filed by AbbVie Inc. (Attachments: # 1 Exhibits A-B, # 2 Civil Cover Sheet)(twk) Modified on 6/6/2023 (nms). (Entered: 02/03/2023) (Civil Cover Sheet) (2)
Menu